ResearchMoz

Avastin (Breast Cancer) Analysis and Forecasts to 2020

GlobalData
Published Date » 2011-12-31
No. Of Pages » 47
 GlobalDatas pharmaceuticals report, Avastin (Breast Cancer)  Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.  Note: This is a on-demand...
Table of Contents

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Estimates Report Guidance 7

3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 18

6 Treatment Options of Breast Cancer 20

6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Avastin (bevacizumab) 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.4 Approval History of Avastin 30
7.5 Factors Affecting Sales of Avastin 31
7.5.1 Breast Cancer Market 31
7.5.2 Efficacy 31
7.5.3 Approval in Japan 31
7.5.4 Withdrawal of Approval in the US and Rejection in the UK 31
7.5.5 EMAs Verdict 31
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 32
7.7.1 Target Patient Pool of Avastin 33
7.7.2 Dosing 33
7.7.3 Market Penetration 34
7.7.4 Annual Cost of Therapy 34
7.7.5 Sales Projections of Avastin 34

8 Breast Cancer Market: Appendix 43
8.1 Market Definitions 43
8.2 Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Contact Us 47
8.5 Disclaimer 47
8.6 Sources 47

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Phase III Clinical Study (E2100) Results for Avastin in Metastatic Breast Cancer 29
Table 5: Approval History of Avastin 30
Table 6: Drug Risk Benefit Score of Avastin 32
Table 7: Avastin, Breast Cancer, The US, The UK, France, Germany, Italy and Spain, Sales Estimates ($m), 20072010 35
Table 8: Avastin, Breast Cancer, France, Germany, Italy, Spain and Japan, Sales Forecasts ($m), 20072020 35
Table 9: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Table 10: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Table 11: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Table 12: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Table 13: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Table 14: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Table 15: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Avastin 33
Figure 34: Avastin, Breast Cancer, Global, Sales Forecasts ($m), 20072020 35
Figure 35: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Figure 36: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Figure 37: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Figure 38: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Figure 39: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Figure 40: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Figure 41: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42
Figure 42: Drug Model Diagram 45
Figure 43: Patients Approved for the Drug 46

Upcoming Reports:

Greece: market of iron or steel tanks, casks, drums and cans
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the iron or steel tanks, casks, drums and cans market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the iron or steel tanks, casks, drums and cans market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In...
Rigid Colored PU Foam Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Rigid colored PU (polyurethane) foams are polyurethanes with closed cell structures. PU foams are manufactured by reacting isocyanates such as methylene diisocyanate (MDI) with polyols in presence of surfactants, blowing agents and several other chemicals such as amines acting as catalysts. The PU foam thus produced is treated with pigments and other coloring agents in order to produce rigid colored PU foams.   The closed cell structure of rigid colored PU foams imparts high strength, stability, energy efficiency and high thermal resistance to the foams. The physical...
Nuts And Seeds Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Nuts and seeds are rich in nutritional value and contain essential nutrients like protein, folate, essential minerals, and fiber. Nuts are defined as dried hard shelled fruits with edible kernel, while seeds are embryonic plants enclosed in seed-coat. Edible seeds are derived from cereals, legumes, and nuts. Seeds and nuts cater to a variety of applications. Nuts are eaten raw, used for cooking, pressed for oil that is used in cooking or cosmetics, or roasted as snack food. Seeds provide many cooking oils, spices and condiments, and some important food additives. The nuts and seeds market...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

World Cup Stadium at Qatar to be Renovated for 2022 FIFA World Cup
Nov 26, 2014  
The design for renovation of the Khalifa International Stadium will soon be unveiled by the organization that is responsible for building the infrastructure and stadiums for the 2022 FIFA World Cup Qatar. The main construction work on the stadium is being looked into by two prominent construction companies. The joint venture is between Six Construct and Midmac Contracting. Six Construct is a...
DOD Spending Low, Corps Look for More Work in Alaska
Nov 24, 2014  
Military construction across Alaska continues to decline. Government contractors expect to keep busy for the time being with work delegated by other federal agencies. The United States Army Corps of Engineers expects to have more than US$410 million worth of work available on at least 400 projects in the 2015 fiscal year. Chris Tew, the Alaska Contracting Division chief said that is...
China Consumer Products Fair Kicks-Off in Abu Dhabi
Nov 24, 2014  
Seeking to market products in the United Arab Emirates (UAE) and Mena regions, more than 100 consumer goods makers from China showcased their mid-to-high-end consumer goods at the China Consumer Products Fair. The second edition of the China Consumer Products Fair 2014 began on Monday in Abu Dhabi’s National Exhibition Center (Adnec). The event was officially inaugurated by the Economic...
Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...